Group 1 - The core viewpoint of the report is that WuXi Biologics has issued an earnings upgrade for the second half of 2025, with expected revenue growth of 17% year-on-year, aligning with market expectations [1] - Adjusted net profit is projected to increase by 31% to 3.7 billion, significantly exceeding market expectations [1] - The gross profit margin is expected to rise by 6.2 percentage points to 48.8%, which is a key positive surprise in this earnings upgrade and the main driver of better-than-expected profit performance [1] Group 2 - In the context of the CRO and CDMO industry in China, WuXi Biologics remains one of the preferred stocks [1] - The target price for WuXi Biologics is maintained at HKD 48.5, with a rating of "outperform" [1]
大行评级丨里昂：药明生物去年下半年经调整纯利远胜预期，续列行业首选